Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (41-50 of 303) with videos related to

Pageof 31
Sort By:
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Cancer Research and Treatment|October 13, 2022
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain MetastasisHongsik Kim, Sehhoon Park, Hyun Ae Jung, et al.
Oncology|November 13, 2010
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatmentSeung Tae Kim, Jeeyun Lee, Jong-Mu Sun, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
BMC Cancer|August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaHyera Kim, Minsuk Kwon, Binnari Kim, et al.
Translational Lung Cancer Research|November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerHyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology|March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinomaJang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research|January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Cancer Research and Treatment|July 26, 2024
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following SurgeryWon Kyung Cho, Jae Myoung Noh, Dongryul Oh, et al.
Pageof 31

Showing results (41-50 of 303) with videos related to

Sort By:
Pageof 31
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Cancer Research and Treatment|October 13, 2022
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain MetastasisHongsik Kim, Sehhoon Park, Hyun Ae Jung, et al.
Oncology|November 13, 2010
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatmentSeung Tae Kim, Jeeyun Lee, Jong-Mu Sun, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
BMC Cancer|August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaHyera Kim, Minsuk Kwon, Binnari Kim, et al.
Translational Lung Cancer Research|November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerHyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology|March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinomaJang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research|January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Cancer Research and Treatment|July 26, 2024
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following SurgeryWon Kyung Cho, Jae Myoung Noh, Dongryul Oh, et al.
Pageof 31